# A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

> **NCT04663308** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 182 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Volixibat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04663308
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-18
- **Primary completion:** 2026-06
- **Final completion:** 2027-04
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663308, "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04663308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*